Prof. Baas and his team found that inhibition of the terminal pathway facilitates regeneration. Many neurodegenerative diseases show activation of the complement system. In some diseases complement activation can already be found in the initial stages of disease. ALS is such a disease. The 'membrane attack complex' can also be detected on nerve-muscle junctions of for example, ALS patients. This could mean that the activation of the complement system is related to progression of ALS. We have strong evidence to suggest that blocking complement activation will delay nerve degeneration and even accelerate nerve regeneration.
Based on these discoveries Regenesance is developing a new drug for nerve regeneration based on state of the art antibody technology. The Regenesance antibodies are directed to C6, an essential component of the MAC. These antibodies will lower the level of C6 in the human body, prevent MAC formation and thus might delay nerve degeneration and even accelerates nerve regeneration.
Alongside Prof. Baas, other key players in this team were Dr. Valeria Ramaglia and Dr. Kees Fluiter. Their research results became the basis for several patents, important publications and led to the founding of Regenesance in 2009. More on our lead scientist can be found in the About section.
Besides ALS, treatments for other indications such as Myasthenia Gravis and Multiple Sclerosis are also in development. In addition, the Regenesance research pipeline includes a small molecule MAC inhibitor which is being developed for acute neurological trauma.